Iboga Nine is an independent information resource on ibogaine for people researching ibogaine. Our mission is straightforward: gather evidence, explain safety and legality clearly, and help readers find the authoritative sources they need without clinical or legal advice.
We compile and summarise evidence using a cautious, source-first methodology. Where claims hinge on clinical studies or legal frameworks we reference original registries, peer-reviewed literature and official government pages so readers can follow the trail to primary sources; for example we rely on public registries such as ClinicalTrials.gov when discussing trial evidence, and refer to authoritative summaries like scientific-method overviews to explain our standards for evaluating studies.
We curate information on evidence, safety considerations, legal context, and practical questions that people researching ibogaine typically ask. Content is organised into topical sections and plain-language explainers, and we provide links to original sources so readers can inspect the evidence themselves. For more on how we organise content and resources, see our description of related offerings on our services overview.
We prioritise primary, citable sources. When summarising clinical evidence we look for peer-reviewed articles and trial registrations; for legal and regulatory context we consult government and regulatory pages. This approach supports traceability — every factual claim that matters is accompanied by a link to the source so readers can verify context and limitations themselves. For regulatory context we consult primary sites such as the U.S. Food and Drug Administration for general standards and publicly available regulatory guidance when appropriate (fda.gov).
Content undergoes editorial checks for sourcing and accuracy. When a claim depends on clinical outcomes or legal interpretation we indicate the level of evidence and provide links to primary registries like ClinicalTrials.gov or to peer-reviewed publications. Where appropriate, we link to university-hosted summaries or official guidance to help clarify methodological issues (harvard.edu).
Iboga Nine is an independent information resource. We are not a clinic, medical provider, or licensed treatment center, and our content does not constitute medical or legal advice. Readers seeking clinical care should consult qualified providers or local regulatory resources; for legal status and regulation, official government pages remain the authoritative source (for instance see national health agency pages or legislation portals).
If you encounter a claim that looks unsourced or unclear, our workflow invites readers to flag issues through the contact page; when appropriate we update the item and add clarifying links back to primary registries and literature. For an example of how we reference trial evidence, see registrations posted on ClinicalTrials.gov.
We follow standard practices for summaries: identify the original study, state sample size and design where relevant, and note limitations. For methodology references we lean on recognized descriptions of evidence assessment such as those found in academic and institutional guidance (peer review).
To explore topical content curated by Iboga Nine, browse our site structure from the main pages; our site navigation makes it easy to move between summaries, safety and legal snapshots, and common questions. If you want a concise path back to the introduction of the site, our landing pages provide a clear starting point linking editorial summaries to original sources across the site, including a practical services overview at our services page.
Photography and source imagery in our explainers are chosen to support clarity and focus; we use images in articles as contextual, not promotional, assets.
